BeyondSpring
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 36
- Market Cap
- -
- Introduction
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the Plinabulin Pipeline and TPD Platform segments. The Plinabulin Pipeline segment focuses on the development of cancer therapies. The TPD Platform segment engages in the development of therapeutic agents and discover chemical entities...
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2
- Conditions
- Interventions
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- BeyondSpring Pharmaceuticals Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT04345900
- Locations
- 🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
🇺🇸Emad Ibrahim, MD, Inc., Redlands, California, United States
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Harbin, China
Plinabulin iv Solution in Prevention of TAC Induced Neutropenia
- Conditions
- Interventions
- First Posted Date
- 2020-01-14
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- BeyondSpring Pharmaceuticals Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT04227990
- Locations
- 🇨🇳
Cancer Center of Guangzhou Medical University Breast Oncology, Guangzhou, Guangzhou, China
🇨🇳Fourth Hospital of Hebei Medical University Breast cancer department, Shijiazhuang, Hebei, China
🇨🇳China-Japan Union Hospital of Jilin University Tumor department of Hematology, Changchun, Jilin, China
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
- Conditions
- Interventions
- First Posted Date
- 2017-09-27
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- BeyondSpring Pharmaceuticals Inc.
- Target Recruit Count
- 221
- Registration Number
- NCT03294577
- Locations
- 🇺🇦
Dnipropetrovsk City Multifunctional Hospital #4 Oncology Department, Dnepropetrovsk, Ukraine
🇺🇦Prykarpatskiy Regional Oncological Center, Ivano-Frankivs'k, Ukraine
🇺🇦V.T. Zaycev Institute, Kharkiv, Ukraine
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3
- Conditions
- Interventions
- First Posted Date
- 2017-04-06
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- BeyondSpring Pharmaceuticals Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT03102606
- Locations
- 🇺🇸
Stanford University School of Medicine - Cancer Institute, Stanford, California, United States
🇺🇸Hematology/Oncology of the North Shore, Skokie, Illinois, United States
🇨🇳Heilongjiang Cancer Hospital, Harbin, Heilongjiang, China
Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- BeyondSpring Pharmaceuticals Inc.
- Target Recruit Count
- 559
- Registration Number
- NCT02504489
- Locations
- 🇺🇸
Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸Peachtree Hematoloy-Oncology Consultants, PC, Atlanta, Georgia, United States
🇨🇳The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China